Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indication. Accompanying these advances, the 2018 Nobel Prize was awarded for the discovery of im...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Chongxian, Liu, Hongtao, Robins, Elizabeth, Song, Wenru, Liu, Delong, Li, Zihai, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119170/
https://www.ncbi.nlm.nih.gov/pubmed/32245497
http://dx.doi.org/10.1186/s13045-020-00862-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119170/
https://www.ncbi.nlm.nih.gov/pubmed/32245497
http://dx.doi.org/10.1186/s13045-020-00862-w

Ejemplares similares